{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:28:42Z","timestamp":1786796922594,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111676","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:59:59Z","timestamp":1782601199000},"page":"111676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumor volume reduction during adaptive radiotherapy is a strong prognostic factor for oropharyngeal cancer: A retrospective multicenter study"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-4599","authenticated-orcid":false,"given":"Seung Gyu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6761-5903","authenticated-orcid":false,"given":"Eunyeong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-8200","authenticated-orcid":false,"given":"Heerim","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongryul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-8472","authenticated-orcid":false,"given":"Yong Chan","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111676_b0005","first-page":"24","volume":"363","author":"Ang","year":"2010","journal-title":"Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer"},{"key":"10.1016\/j.radonc.2026.111676_b0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2016.09.006","article-title":"Treatment de-intensification strategies for head and neck cancer","volume":"68","author":"Kelly","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111676_b0015","first-page":"164","article-title":"Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer","volume":"73","author":"Kang","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2026.111676_b0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11912-025-01652-8","article-title":"De-escalation for human papillomavirus-positive oropharyngeal cancer: a look at the prospective evidence","volume":"27","author":"Chen","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.radonc.2026.111676_b0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111676_b0035","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111676_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115343","article-title":"Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial","volume":"220","author":"Palma","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111676_b0050","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group Study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111676_b0055","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2020.12.021","article-title":"Costs of definitive chemoradiation, surgery, and adjuvant radiation versus de-escalated adjuvant radiation per MC1273 in HPV+ cancer of the oropharynx","volume":"110","author":"Waddle","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111676_b0060","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.canrad.2025.104674","article-title":"Intensification or de-escalation? what is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?","volume":"29","author":"Blanchard","year":"2025","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.radonc.2026.111676_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1594765","article-title":"Intensifying adjuvant therapy in intermediate-risk head and neck cancer: navigating the gray zone, selecting the right patient","volume":"15","author":"Mohanty","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hed.23328","article-title":"Tumor volume reduction rate measured during adaptive definitive radiation therapy as a potential prognosticator of locoregional control in patients with oropharyngeal cancer","volume":"36","author":"Lee","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2026.111676_b0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4143\/crt.2015.081","article-title":"Tumor volume reduction rate during adaptive radiation therapy as a prognosticator for nasopharyngeal cancer","volume":"48","author":"Lee","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111676_b0085","series-title":"AJCC cancer staging manual (7th ed)","year":"2010"},{"key":"10.1016\/j.radonc.2026.111676_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4143\/crt.2020.572","article-title":"Development of a tongue immobilization device using a 3D printer for IMRT of nasopharyngeal cancer patients","volume":"53","author":"Ju","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111676_b0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4143\/crt.2018.240","article-title":"Feasibility of selective neck irradiation with lower elective radiation dose in treating nasopharynx cancer patients","volume":"51","author":"Cho","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111676_b0100","article-title":"Reduced dose and selective neck irradiation policy in treating oropharynx cancer: excellent oncological outcomes with very low risk of locoregional failure","author":"Yang","year":"2025","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111676_b0105","article-title":"National Cancer Institute. Common Terminology Criteria for adverse events (CTCAE)","volume":"5","author":"U.S. Department of Health and Human Services NIoH","year":"2017","journal-title":"Version"},{"key":"10.1016\/j.radonc.2026.111676_b0110","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.24.00119","article-title":"Radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: final results of the ORATOR randomized trial","volume":"42","author":"Nichols","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106248","article-title":"30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: a retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675)","volume":"137","author":"Haller","year":"2023","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijrobp.2022.05.047","article-title":"Long-Term toxic Effects, Swallow Function, and Quality of Life on MC1273: a phase 2 study of dose de-escalation for adjuvant chemoradiation in human papillomavirus-positive oropharyngeal cancer","volume":"114","author":"Price","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111676_b0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: an ASTRO Clinical Practice Guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0130","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO-24-02550","article-title":"Long-term follow-up of E3311, an ECOG-ACRIN Cancer Research Group phase II trial of transoral surgery and risk-based adjuvant treatment in human papillomavirus-initiated oropharynx cancer","volume":"43","author":"Burtness","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0135","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim Futility results of NRG-HN005, a Randomized, phase II\/III Non-Inferiority Trial for Non-smoking p16+ Oropharyngeal Cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111676_b0140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40336-023-00607-y","article-title":"Is there a role for [(18)F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature","volume":"12","author":"Sambasivan","year":"2024","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.radonc.2026.111676_b0155","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-3978-3","article-title":"FDG-PET\/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance","volume":"45","author":"Helsen","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2026.111676_b0160","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111676_b0165","article-title":"Adaptive FDG-PET\/CT guided dose escalation in head and neck squamous cell carcinoma: late toxicity and oncologic outcomes (the ADMIRE study)","volume":"43","author":"Al-Mamgani","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111676_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110281","article-title":"A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)","volume":"196","author":"de Leeuw","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:19:46Z","timestamp":1786796386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S0167814026005153"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111676","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor volume reduction during adaptive radiotherapy is a strong prognostic factor for oropharyngeal cancer: A retrospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111676"}}